Web Results

www.pulmonaryfibrosis.org/life-with-pf/clinical-trials/pipeline

Jul 17, 2020 ... Drug Development Pipeline - PF & IPF · Have a question about what one of the filter terms means? · We are interested in enhancing this PF Drug&n...

www.covance.com/latest-thinking/explore-library/detail.html/covance/assetLibrary/salessheets/IPF-Drug-Dev-Infosheet-SSCDS109.pdf

Aug 13, 2020 ... Join Covance at the IPF Summit and hear the latest strategies for helping patients with idiopathic pulmonary fibrosis. Meet with our specialists ...

erj.ersjournals.com/content/45/5/1218

Efficient IPF drug development is needed to ensure unmet medical need isn't ... pulmonary fibrosis (IPF) remains a high-risk disease area for drug development.

www.ajmc.com/view/emerging-therapeutic-innovations-for-treatment-of-idiopathic-pulmonary-fibrosis

Jan 17, 2020 ... Study authors note that while the recent introduction of antifibrotic drugs pirfenidone and ... The development of biomarkers to personalize therapy for IPF is a...

pubmed.ncbi.nlm.nih.gov/32538186

Jun 24, 2020 ... The approval of pirfenidone and nintedanib has fueled IPF drug discovery and development. New drugs are likely to reach the clinic in the near ...

pubmed.ncbi.nlm.nih.gov/29718783

May 8, 2018 ... Areas covered: The development of two antifibrotic agents, nintedanib and pirfenidone has been an exciting landmark in the treatment of IPF.

innovations.clevelandclinic.org/Programs/Top-10-Medical-Innovations/Top-10-for-2015/8-New-Medications-for-Idiopathic-Pulmonary-Fibros

Some people develop IPF after receiving radiation therapy for lung or breast cancer, while others develop the chronic lung damage after chemotherapy ...

bmcmedicine.biomedcentral.com/articles/10.1186/s12916-015-0480-7

Sep 24, 2015 ... IPF drug discovery between present and future. To date, 12 medicinal products, most in preclinical phase of development, have obtained orphan ...

www.biopharmadive.com/news/roche-promedior-acquisition-ipf-fibrosis/567447

Nov 15, 2019 ... Roche's Esbriet is one of two drugs approved to treat IPF, and came under the ... as it continues developing PRM-151 for IPF and myelofibrosis.

www.astrazeneca.com/media-centre/press-releases/2019/us-fda-grants-saracatinib-orphan-drug-designation-for-idiopathic-pulmonary-fibrosis-18032019.html

Mar 18, 2019 ... Saracatinib has completed Phase I development. IPF is a chronic, progressive, irreversible and usually fatal interstitial lung disease1 which ...